In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth/Interneuron Redux descheduling proposal by DEA issues one year after approval of obesity agent.

Executive Summary

DEA TO CONTINUE TO MONITOR FENFLURAMINE ABUSE POTENTIAL FOLLOWING DESCHEDULING of the agent and its isomers, including dexfenfluramine (Wyeth-Ayerst/Interneuron's Redux), the Drug Enforcement Administration stated in a May 6 notice proposing to remove fenfluramine (Wyeth's Pondimin) from Schedule IV of the Controlled Substances Act. "In light of the increasing availability and use of fenfluramine, particularly in combination with phentermine, and possible public health and safety risks including neurotoxicity, primary pulmonary hypertension and reports that fenfluramine may have pharmacological similarity to some hallucinogenic substances, DEA will carefully monitor the abuse, trafficking and diversion indicators regarding this substance," the notice states.



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts